Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study
IntroductionProton pump inhibitor (PPI) use has been associated with reduced immune checkpoint inhibitor (ICI) efficacy in metastatic non-small cell lung cancer (mNSCLC) with evidence limited to their use during a short time period around ICI initiatio…